Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 13/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761752 | 0.88 | SMN1; SMN2 (0.42) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL6280976 | 0.77 | SMN1; SMN2 (0.41) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL6189868 | 0.73 | SMN1; SMN2 (0.44) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL7672577 | 0.70 | SMN1; SMN2 (0.46) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL7467972 | 0.70 | SMN1; SMN2 (0.41) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL351651 | 0.68 | SMN1; SMN2 (0.73) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL7679543 | 0.68 | SMN1; SMN2 (0.43) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL6950463 | 0.67 | SMN1; SMN2 (0.46) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL8315006 | 0.67 | GRIN2B (0.58) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL23539139 | 0.67 | SMN1; SMN2 (0.67) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852727-B2 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | GRIN2B 3553/4885SMN1; SMN2 4534/4885NPC1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.